The present invention is drawn to artificial metalloenzymes for use in cyclopropanation reactions, amination and C—H insertion.

The present invention is drawn to artificial metalloenzymes for use in cyclopropanation reactions, amination and C—H insertion.

The present disclosure is in the field of ‘pharmacognosy’ and ‘chemistry of natural products’. The present disclosure generally relates to a process of isolation and purification of Biochemical Constituents from algae. The present disclosure particularly relates to a process of isolation and purification of Biochemical Constituents from a biomass of cyanobacteria. The present disclosure provides a process for isolating and extracting phycocyanins, chlorophylls, proteins and polysaccharides from the spirulina biomass.

Disclosed herein is iCP-mParkin. The iCP-mParkin exhibits biological features suitable for treating neuronal cell damage-related diseases. Thus, the iCP-mParkin provided herein can be used in a composition or method for treating, preventing, or alleviating Parkinson's disease, Alzheimer's disease, and Huntington's disease. Furthermore, the iCP-mParkin is higher in stability than conventional iCP-Parkin and as such, is suitable for use as a protein medicine. In addition, the iCP-mParkin obtained by the preparation method provided herein is of high purity and the preparation method is suitable for mass production.

The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.

The invention provides polymeric H-NOX proteins for the delivery of oxygen with longer circulation half-lives compared to monomeric H-NOX proteins. Polymeric H-NOX proteins extravasate into and preferentially accumulate in tumor tissue for sustained delivery of oxygen. The invention also provides the use of H-NOX proteins as radiosensitizers for the treatment of brain cancers.

Disclosed herein are potency assays for a gene therapy treatment for β-thalassemia. Also disclosed herein are methods for measuring relative potency of a drug product.

Disclosed herein are potency assays for a gene therapy treatment for β-thalassemia. Also disclosed herein are methods for measuring relative potency of a drug product.

The present invention relates to a process for the cultivation of unicellular red algae (URA) optimized for the valorization of the culture products, both the biomass obtained, the phycocyanins extracted therefrom or other culture products such as porphyrins or protein extracts.

The present invention relates to a process for the cultivation of unicellular red algae (URA) optimized for the valorization of the culture products, both the biomass obtained, the phycocyanins extracted therefrom or other culture products such as porphyrins or protein extracts.